Business Wire

SAMSUNG-ELECTRONICS

25.6.2024 12:14:26 CEST | Business Wire | Press release

Share
Samsung Electronics Announces Successful Building of Industry-First CXL Infrastructure Certified by Red Hat

Samsung Electronics Co., Ltd., the world leader in advanced memory technology, today announced that for the first time in the industry, it has successfully built a Compute Express Link™ (CXL™) infrastructure certified by Red Hat, the world’s leading provider of open source solutions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240625016573/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Samsung Electronics Announces Successful Building of Industry-First CXL Infrastructure Certified by Red Hat (Photo: Business Wire)

Elements that configure servers, from CXL-related products to software, can now be directly verified at the Samsung Memory Research Center (SMRC) located in Hwaseong, South Korea. Once CXL products are verified by Samsung, they can immediately be requested for product registration to Red Hat, enabling faster product development.

Marking its first achievement through the infrastructure, Samsung has successfully verified its CMM-D product for the first time in industry this month. The company can also provide tailored solutions to customers by optimizing products at earlier development stages.

“We’re very pleased that our partnership with Red Hat is able to deliver CXL memory products with enhanced reliability to our customers,” said Taeksang Song, Vice President and Head of the New DRAM Solution Development Team at Samsung Electronics. “Through our continued collaboration spanning software and hardware, we will remain at the forefront of developing innovative memory solutions as well as the CXL ecosystem.”

Kyeong Sang Kim, Red Hat Korea GM said, “The optimization of Samsung’s hardware for Red Hat’s software underscores the value of open source technology as an imperative when it comes to expanding next generation memory solutions such as CMM-D. We look forward to continuing our collaboration with Samsung to further extend CXL solutions to the market.”

Following the successful CXL memory verification by Red Hat for the first time in the industry last December, Samsung has also been certified for datacenter SSD products. Customers using Red Hat-certified products can build high-performance systems by receiving world-class Linux support, complementing the stable hardware operation of Samsung.

Samsung and Red Hat have also been working closely together in various areas, including product certification for both hardware and software, enriching the next-generation CXL ecosystem.

At the Red Hat Summit held in Denver, Colorado, in May, Samsung demonstrated its CMM-D1 embedded in Red Hat Enterprise Linux 9.3, which enhances the performance of Deep Learning Recommendation Models (DLRM).

The demo utilized the Scalable Memory Development Kit's (SMDK) Memory Interleaving software technology, highlighting improved memory access performance. SMDK-equipped CMM-D allows customers to build high-performance AI models, without having to make significant investments, by accelerating the data processing, AI learning and inferencing speeds.

Through their strong partnership, Samsung and Red Hat aim to provide customer solutions suitable for a wide range of user systems while introducing new technology standards to an array of partners and customers and expanding the CXL memory ecosystem.

1 CMM-D is Samsung’s CXL Memory Module DRAM, a DRAM solution based on the PCIe interface that supports the CXL protocol.

About Samsung Electronics Co., Ltd.

Samsung inspires the world and shapes the future with transformative ideas and technologies. The company is redefining the worlds of TVs, smartphones, wearable devices, tablets, home appliances, network systems, and memory, system LSI, foundry and LED solutions, and delivering a seamless connected experience through its SmartThings ecosystem and open collaboration with partners. For the latest news, please visit the Samsung Newsroom at news.samsung.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240625016573/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

NIQ Expands ConnectAI Charter Program with Mars Snacking22.10.2026 12:45:00 CEST | Press release

Mars joins a growing group of global companies working with NIQ forward-deployed engineers to bring proprietary consumer and market intelligence into enterprise AI workflows NielsenIQ (NYSE: NIQ), a leading consumer intelligence company, today announced Mars as a new ConnectAI Charter client, expanding the program’s growing roster of global companies working with NIQ to build the intelligence foundation for amplifying enterprise AI workflows. Through the ConnectAI Charter Program, NIQ forward-deployed engineers and data scientists are working with Mars to embed NIQ intelligence in the expansion of AI-enabled workflows across its business. The engagement focuses on connecting NIQ data, models, and business context with Mars’ AI ecosystem to help reduce the distance between data and decision-making. Together, they are tackling use cases like conversational analytics and harmonized product data to lay the foundation for future use cases. “As we expand the use of AI across our business, we

Spotlight Medical Announces Successful Independent Evaluation of Its Digital Slide-Based Test for Assessing Recurrence Risk in Early Breast Cancer22.10.2026 12:18:00 CEST | Press release

An independent, blinded evaluation of 620 patients from the phase III PANTHER trial identified nearly one-quarter as Low Risk despite clinically high-risk breast cancer, with favorable ten-year outcomes. Spotlight Medical, a company developing AI-powered prognostic tests in oncology, today announced results from an independent evaluation of myStage Dx, its CE-IVDR-marked test for assessing recurrence risk in patients with hormone receptor-positive, HER2-negative early breast cancer. The study was conducted by researchers at Karolinska Institutet in Sweden. Independent, Blinded Evaluation Using Phase III Trial Data The study used data from 620 patients enrolled in PANTHER, an international randomized phase III trial comparing dose-dense with standard chemotherapy. myStage Dxpredictions were generated blinded to clinical outcomes. Researchers at Karolinska Institutet linked the predictions to patient outcomes and independently assessed prognostic performance according to a prespecified p

Zoomtopia: Zoom lancerer nye AI-funktioner22.10.2026 12:13:00 CEST | Pressemeddelelse

Zoom vil forkorte vejen fra mødebeslutning til udført arbejde. På konferencen Zoomtopia præsenterer virksomheden Unified Context Layer – et fælles informationslag, der forbinder samtaler, dokumenter og data, så AI kan forstå sammenhængen og hjælpe med de næste skridt. Samtidig lanceres flere nye AI-produkter og -funktioner, der skal gøre det lettere at omsætte diskussioner og beslutninger til handling. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20261021318859/da/ I møder og samtaler træffes vigtige beslutninger, og virksomheder får værdifuld indsigt i deres kunder. En kundedialog kan begynde i et møde, fortsætte i telefonen og derefter gå over i en chat. Når informationen spredes mellem forskellige værktøjer, bliver det svært for både medarbejdere og AI-agenter at få et samlet billede af, hvad der er blevet sagt og besluttet. Resultatet er, at værdifuld tid går med at finde ud af, hvad der er blevet sagt og besluttet, og

TACTICAAI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron22.10.2026 12:01:00 CEST | Press release

Collaboration brings together TACTICAAI’s operational decision-intelligence technology and NVIDIA AI capabilities to advance reasoning, autonomous analysis and video intelligence for real-world deployment TACTICAAI, an operational decision-intelligence company, today announced a collaboration with NVIDIA to advance and scale the deployment of agentic AI capabilities. The companies will work together to integrate and optimize NVIDIA Nemotron models within TACTICAAI’s multi-intelligence platform, with a focus on expanding these capabilities and supporting deployment with major customers internationally. The collaboration was announced at NVIDIA GTC Berlin. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261022054475/en/ TACTICA AI and NVIDIA Collaborate to Scale Agentic AI Capabilities with NVIDIA Nemotron (Graphic: AETOSWire) The collaboration with NVIDIA builds on the company’s existing technology, integrating selected NVIDIA

BeOne Medicines to Announce Third Quarter 2026 Financial Results on November 522.10.2026 12:01:00 CEST | Press release

BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its third quarter 2026 financial results on Thursday, November 5, 2026, before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The live webcast of this event can be accessed from the investors section of the Company’s website at https://ir.beonemedicines.com.To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website. About BeOne Medicines BeOne Medicines is a global oncology company that is discovering and developing innovative treatments for cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye